Compare Stocks

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche since our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative life science, agtech, and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a total market capitalization of $33.1 billion and an asset base in North America of 73.5 million SF as of December 31, 2023, which includes 42.0 million RSF of operating properties, 5.5 million RSF of Class A/A+ properties undergoing construction and one near-term project expected to commence construction in the next two years, 2.1 million RSF of priority anticipated development and redevelopment projects, and 23.9 million SF of future development projects. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in life science, agtech, and advanced technology mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science, agrifoodtech, climate innovation, and technology companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

The B.A.D. ETF (BAD) is an exchange-traded fund that is based on the EQM BAD index. The fund tracks a modified equal-weighted index of US-listed companies engaged in betting, alcohol, cannabis, and drugs. BAD was launched on Dec 22, 2021 and is managed by The BAD Investment Company.

iShares Government/Credit Bond ETF (the Fund) is an exchange-traded fund. The Fund seeks to track the investment results of an index composed of the United States dollar-denominated government, government-related and investment-grade the United States corporate bonds. The Fund seeks to track the investment results of the Barclays U.S. Government/Credit Bond Index (the Underlying Index), which measures the performance of the United States dollar-denominated United States Treasury bonds, government-related bonds (i.e., the United States and foreign agencies, sovereign, supranational and local authority debt) and investment-grade United States corporate bonds, which have a remaining maturity of greater than or equal to one year. The Underlying Index may include large-, mid- or small-capitalization companies, and components include agency and treasury securities, and financial and industrials companies. BlackRock Fund Advisors serves as investment adviser of the Fund.

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.